Of course any positive announcements regarding the rest of the pipeline should impact SP. But in the near term what I am waiting for is some sales figures on Axiron. I'm sure ACR marketing will be making revised projections of market share on a monthly basis in the early days but as to when we will see any data I'm not sure. RBS morgans made the following 12 mth SP projections based on Axiron market share:
$3.92 (30% market share) $5.30 (50% market share)
Given Axiron's competitive advantages RBS consider 30% market share to be conservative (full report available on Acrux website). I tend to agree with RBS when you consider the Axiron option of a fast drying underarm spray to treat testosterone deficiency compared to a sticky gel you rub between your thighs, an injection or patches, I know which one I'll be going for when I need it!
Good market penetration combined with an extention to the Axiron patent would be the icing on the cake!
ACR Price at posting:
$3.12 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)